| Aspect | Key finding | Evidence type | Source (with year) | Notes/limitations |
|---|---|---|---|---|
| Identity | Human **LYPD2** encodes **Ly6/PLAUR domain-containing protein 2**; UniProt **Q6UXB3** | Review/database summary | Rathbun et al., 2023; Loughner et al., 2016 | Rathbun table explicitly lists Q6UXB3; Loughner lists aliases and family placement (pqac-00000005, pqac-00000007) |
| Genomic location | Located on **chromosome 8q24.3** and reported to have **3 exons** | Review/database summary | Loughner et al., 2016 | Family/genome annotation rather than direct functional experiment (pqac-00000007) |
| Domain architecture | Encodes a **single LU (Ly6/uPAR) domain** consistent with the Ly6/uPAR superfamily | Review | Loughner et al., 2016; Kong & Park, 2012 | Structural assignment is family-based; no LYPD2-specific structure solved in provided context (pqac-00000007, pqac-00000003) |
| Localization | Annotated as **cell surface (CS)** | Database-style table / review | Rathbun et al., 2023 | Table-level annotation; not a direct localization experiment in the cited excerpt (pqac-00000001, pqac-00000005, pqac-00000010) |
| Localization / anchoring inference | As a Ly6/uPAR family cell-surface member, LYPD2 is placed in the **GPI-anchored subgroup** with extracellular LU-domain architecture | Review / inference from family classification | Kong & Park, 2012 | This is an inference from family classification, not direct biochemical confirmation of a GPI anchor for human LYPD2 in the provided context (pqac-00000003) |
| Normal tissue expression | GTEx summary indicates highest expression in **esophagus** (**>250 TPM**), with lower expression in **skin** and **vagina** | Database-style table | Rathbun et al., 2023 | Numeric tissue expression comes from table image/context; tissue-level RNA only, not protein localization or function (pqac-00000010, pqac-00000005) |
| Normal tissue expression | Human Protein Atlas-based summary states **LYPD2 RNA is expressed in esophagus and tonsil** | Review/database summary | Upadhyay, 2019 | Qualitative statement; no TPM values given in this excerpt (pqac-00000004) |
| Reported function | **No known or proposed function available** in the human LY6 family table | Database-style table / review | Rathbun et al., 2023 | Strong evidence gap for human-specific mechanism; no validated ligand, receptor, or pathway in provided human literature (pqac-00000001, pqac-00000005) |
| Family-level functional analogy | Mouse-focused family table lists **LYPD2** as an **α4β2 nAChR modulator** | Review summarizing mouse evidence | Loughner et al., 2016 | This row is for **mouse** Ly6/uPAR family evidence, not direct evidence for human LYPD2; should not be overinterpreted (pqac-00000008) |
| Experimental interaction testing | A 2022 study reported **no interaction** between **mouse lypd2** and **GluR2Q/GluR2R AMPA receptor** isoforms | Experimental (mouse) | Lauriello et al., 2022 | Useful negative evidence for family hypotheses, but species-specific and not direct evidence for human LYPD2 function (pqac-00000002) |
| Single-cell expression | **LYPD2-high/VMO1-high** marks one **non-classical monocyte** subset in integrated scRNA-seq from autoimmune diseases | High-throughput single-cell transcriptomics | Luo et al., 2023 | Marker-gene evidence only; excerpt gives no LYPD2-specific effect size, fold-change, or mechanistic role (pqac-00000009) |
| Cancer-associated expression | Review states LYPD2 RNA is higher than adjacent normal tissue in **cervical** and **head and neck** cancers and associated with **favorable prognosis** in Human Protein Atlas analyses | Review/database mining | Upadhyay, 2019 | Secondary summary; no cohort size or hazard statistics provided in excerpt (pqac-00000006) |
| UCEC association | In **uterine corpus endometrial carcinoma (UCEC)**, **no significant change** in LYPD2 mRNA expression was reported | In silico tumor expression analysis | Rathbun et al., 2023 | Negative result in one cancer type; does not exclude relevance in others (pqac-00000001, pqac-00000005) |
| Screening evidence / host-pathogen context | In focused CRISPR knockout screens of predicted GPI-anchored proteins, **LYPD2 was among top-10 enriched genes in each infection condition** and was identified in **all four coronavirus screens** | High-throughput functional genomics | Ma et al., 2025 | Recurrent screen hit suggests relevance, but provided excerpt does not show LYPD2-specific validation phenotype or mechanism; LY6E, not LYPD2, was the lead validated hit (pqac-00000011, pqac-00000012) |
| Disease associations | Open Targets lists low-to-moderate evidence links to **neurodegenerative disease**, **thrombocytopenia**, **X-linked severe congenital neutropenia**, **autosomal dominant macrothrombocytopenia**, and **Blackfan-Diamond anemia** | Database association mining | Open Targets | Associations appear driven by limited evidence and should be treated as hypothesis-generating rather than causal/validated for LYPD2 biology (pqac-00000000) |


*Table: This table compiles the main supported findings for human LYPD2 (Q6UXB3), separating direct human evidence from family-based inference and non-human data. It is useful for identifying what is known, what is only predicted, and where major evidence gaps remain.*